BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Otsuka Holdings readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Otsuka Holdings's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05392114-10797@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dawnzera (Donidalorsen): Phase 3 readout est. (NCT05392114)
DESCRIPTION:Dawnzera (Donidalorsen)\, phase 3\, Hereditary Angioedema.\nStu
 dy: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in
  the Prophylactic Treatment of Hereditary Angioedema (HAE)\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/donidalorsen#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05392114
URL:https://assetmemo.bio/drug/donidalorsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07173478-1444@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Moizerto / Adquey (difamilast): Phase 3 readout est. (NCT07173478)
DESCRIPTION:Moizerto / Adquey (difamilast)\, phase 3\, Atopic Dermatitis.\n
 Study: A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam
  to the Vehicle in Adult Patients With Atopic Dermatitis\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/difamilast#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07173478
URL:https://assetmemo.bio/drug/difamilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184645-1444@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Moizerto / Adquey (difamilast): Phase 3 readout est. (NCT07184645)
DESCRIPTION:Moizerto / Adquey (difamilast)\, phase 3\, Atopic Dermatitis.\n
 Study: A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atop
 ic Dermatitis\nEstimated primary completion: February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/difamilast#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07184645
URL:https://assetmemo.bio/drug/difamilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759154-825@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Simtriyo (Centanafadine): Phase 3 readout est. (NCT07759154)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 3\, Attention Deficit Hyperact
 ivity Disorder.\nStudy: A Study to Test the Effects of Centanafadine in Ad
 ults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregula
 tion\nEstimated primary completion: 27 May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/centanafadine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07759154
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086313-825@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Simtriyo (Centanafadine): Phase 2/3 readout est. (NCT07086313)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 2/3\, Attention Deficit Hypera
 ctivity Disorder.\nStudy: A Trial to Evaluate the Efficacy and Safety of E
 B-1020 in Pediatric Patients With ADHD\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/centanafadin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 086313
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087327-825@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Simtriyo (Centanafadine): Phase 3 readout est. (NCT07087327)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 3\, Attention Deficit Hyperact
 ivity Disorder.\nStudy: A Long-term Trial of EB-1020 in Pediatric Patients
  With ADHD\nEstimated primary completion: August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/centanafadine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07087327
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05325645-666@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Brexpiprazole (Rexulti): Phase 3 readout est. (NCT05325645)
DESCRIPTION:Brexpiprazole (Rexulti)\, phase 3\, Schizophrenia.\nStudy: Tria
 l of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Sch
 izophrenia\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05325645
URL:https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931080-825@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Simtriyo (Centanafadine): Phase 2/3 readout est. (NCT06931080)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 2/3\, Attention Deficit Hypera
 ctivity Disorder.\nStudy: Evaluation of the Efficacy and Safety of EB-1020
  in Adult ADHD Patients\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/centanafadine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06931080
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926829-825@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Simtriyo (Centanafadine): Phase 3 readout est. (NCT06926829)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 3\, Attention Deficit Hyperact
 ivity Disorder.\nStudy: A Long-term Trial of EB-1020 in Adult Patients Wit
 h ADHD\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/centanafadine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06926829
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04093570-2362@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT04093570
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Acute Myeloid Leuk
 emia.\nStudy: A Study for Participants Who Participated in Prior Clinical 
 Studies of ASTX727 (Standard Dose)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/decitabine-
 cedazuridine-inqovi#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04093570
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03934372-10794@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:ICLUSIG (Ponatinib): Phase 1/2 readout est. (NCT03934372)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 1/2\, Chronic Myeloid Leukemia.\nSt
 udy: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent
  or Refractory Leukemias\, Lymphomas or Solid Tumors\nEstimated primary co
 mpletion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03934372
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225712-857@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07225712)
DESCRIPTION:Ulotaront\, phase 3\, Schizophrenia.\nStudy: A Long-term Admini
 stration Trial of SEP-363856 in Patients With Schizophrenia\nEstimated pri
 mary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ulotaront#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07225712
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767903-857@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281025
DTEND;VALUE=DATE:20281026
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07767903)
DESCRIPTION:Ulotaront\, phase 3\, Generalized Anxiety Disorder.\nStudy: A T
 rial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults Wi
 th Generalized Anxiety Disorder\nEstimated primary completion: 25 October 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ulotaront#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07767903
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759128-857@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281206
DTEND;VALUE=DATE:20281207
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07759128)
DESCRIPTION:Ulotaront\, phase 3\, Generalized Anxiety Disorder.\nStudy: A T
 rial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults Wit
 h Generalized Anxiety Disorder\nEstimated primary completion: 6 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ulotaront#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07759128
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04782258-588@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281228
DTEND;VALUE=DATE:20281229
SUMMARY:Samsca (Tolvaptan): Phase 3 readout est. (NCT04782258)
DESCRIPTION:Samsca (Tolvaptan)\, phase 3.\nStudy: A Study to See if Tolvapt
 an is Safe in Infants and Children Who at Enrollment Are 28 Days to Less T
 han 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD
 )\nEstimated primary completion: 28 December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tolvaptan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04782258
URL:https://assetmemo.bio/drug/tolvaptan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07786454-857@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290526
DTEND;VALUE=DATE:20290527
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07786454)
DESCRIPTION:Ulotaront\, phase 3\, Generalized Anxiety Disorder.\nStudy: A T
 rial of the Safety and Tolerability of SEP-363856 in Adults With Generaliz
 ed Anxiety Disorder\nEstimated primary completion: 26 May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ulotaront#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07786454
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298447-10797@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Dawnzera (Donidalorsen): Phase 3 readout est. (NCT07298447)
DESCRIPTION:Dawnzera (Donidalorsen)\, phase 3\, Hereditary Angioedema.\nStu
 dy: Donidalorsen Treatment in Children With Hereditary Angioedema\nEstimat
 ed primary completion: June 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/donidalorsen#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07298447
URL:https://assetmemo.bio/drug/donidalorsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
